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Abstract
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Aim To determine how basic fibroblastic growth factor
(bFGF) affected the osteogenic differentiation of human
dental pulp stem cells (DPSCs) in vitro and in vivo.
Methodology Basic fibroblastic growth factor stimu-
lation of DPSCs was divided into a pre-treatment period
and an osteogenic differentiation period. Alizarin red
quantification experiments and alkaline phosphatase
activity quantification assay were performed to examine
the osteogenic differentiation of DPSCs after different
bFGF stimulation. Quantification reverse transcription
polymerase chain reaction was used to analyze the oste-
ogenic gene expression of DPSCs after different bFGF
stimulation. In addition, DPSCs that received the 1 and
2 weeks bFGF pre-treatments as in the in vitro experi-
ments were mineralized for 1 week and seeded into
hydroxyapatite/tricalcium phosphate (HA/TCP) pills
and subcutaneously transplanted into naked mice for 2
or 3 months. The transplants were removed, sliced and
stained using Modified Ponceau Trichrome Stain to
observe the formation of mineralized tissue.
Results Basic fibroblastic growth factor stimulation
in the osteogenic differentiation period decreased the
in vitro osteogenic differentiation ability of DPSCs. One
week pre-treatment with bFGF increased the in vitro
osteogenic differentiation ability of DPSCs, whereas
2 weeks pre-treatment with bFGF decreased the
in vitro osteogenic differentiation ability of DPSCs. The
pre-treatment period was vital for the osteogenic dif-
ferentiation of DPSCs in vitro. The in vivo results were
similar to the in vitro results.
Conclusions Basic fibroblastic growth factor
affected the osteogenic differentiation of DPSCs in a
treatment-dependent manner both in vitro and in vivo.
Keywords: basic fibroblast growth factor, dental
pulp stem cells, osteogenic differentiation.
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Introduction
Oral stem cells include dental pulp stem cells (DPSCs),
periodontal ligament stem cells and stem cells from
the apical papilla, Gronthos et al. (2000) first reported
that stem cells isolated from adult dental pulp could
be cultured in vitro. In addition, this type of cell could
differentiate into odontoblasts and could form den-
tine-like tissue. Since then, the concept of DPSCs has
been proposed. DPSCs have been characterized as cells
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that are capable of self-regeneration, have a high
degree of proliferation and have the potential to differ-
entiate into multiple types of cells.
Basic fibroblastic growth factor (bFGF) is a mito-
genic cationic peptide that consists of 155 amino
acids that is extensively distributed throughout the
human body. As a cell mitogen, it mainly impacts on
mesoblasts and neuroderm-oriented cells, such as
skeletal muscle cells, fibroblasts and osteocytes. Corre-
spondingly, its receptor is expressed on these cells. In
addition to its mitogenic effects, bFGF is a morpho-
genesis and differentiation inducer. The main biologi-
cal effects of bFGF include (i) its role as an angiogenic
factor, (ii) its promotion of wound healing and tissue
restoration, (iii) its promotion of tissue regeneration,
and (iv) its participation in neurogenesis (Davidson
et al. 1985, Lobb et al. 1985, Abraham et al. 1986,
Cuny et al. 1986, Canalis et al. 1987).
Many in vivo studies have shown that bFGF can
induce bone regeneration (Mayahara et al. 1993,
Nakamura et al. 1995, Zellin & Linde 2000). How-
ever, the in vitro effects of bFGF on cell osteogenic dif-
ferentiation remain unclear. Some studies have
shown that stimulation with bFGF inhibited the pro-
duction of collagen and alkaline phosphatase (ALP)
and the osteogenic differentiation of osteoblasts (Ca-
nalis et al. 1988, Varghese et al. 1995, Tang et al.
1996). In contrast, other reports have shown that
bFGF enhanced the osteogenic differentiation of multi-
potent stem cells (MSCs), and osteoblasts if the cells
were exposed to bFGF only during the late periods of
cell osteogenic differentiation (Debiais et al. 1998,
Tsutsumi et al. 2001, Fakhry et al. 2005). In addi-
tion, it has been demonstrated that bFGF could
induce the dexamethasone-dependent osteogenic dif-
ferentiation of MSCs and that combined treatment
with bFGF and BMP-2 synergistically enhanced the
osteogenic potency of bFGF in MSC cultures (Hanada
et al. 1997).
Several years ago, researchers began to focus on
the relationship between bFGF and human dental
pulp cells (HDPCs)/DPSCs (He et al. 2008, Kim et al.
2010, Osathanon et al. 2011). However, similar dis-
agreement was found regarding the in vitro effects of
bFGF on HDPCs/DPSCs. Some articles have reported
that bFGF increased ALP activity and enhanced osteo-
genic differentiation in the HDPCs/DPSCs (He et al.
2008, Kim et al. 2010). However, other reports
showed that bFGF inhibited the osteogenic differentia-
tion of HDPCs/DPSCs (Shimabukuro et al. 2009,
Osathanon et al. 2011). A review of these articles on
bFGF and HDPCs/DPSCs revealed that the stature of
the cells and the treatment protocol of bFGF were dif-
ferent. (Shiba et al. 1995, He et al. 2008, Shimabuk-
uro et al. 2009, Kim et al. 2010, Osathanon et al.
2011). Therefore, an experiment was designed that
was as comprehensive as possible to determine the
relationship between bFGF and the osteogenic differ-
entiation of DPSCs in vitro and in vivo.
Hydroxyapatite/tricalcium phosphate (HA/TCP) has
been commonly used as a scaffold material for in vivo
experiments in stem cell research. Its biological char-
acteristics make it suitable for use in stem cell
research, especially for in vivo osteogenic differentia-
tion assays (Zhang et al. 2006). Shi et al. (2005) used
this material to observe the osteogenic characteristics
of MSCs (mesenchymal stem cells). Therefore, HA/
TCP was used in the classic manner, which involves
seeding DPSCs into HA/TCP and inserting the com-
plex into the backs of naked mice to observe how the
in vivo osteogenic differentiation of the DPSCs was
affected by bFGF stimulation, according to the treat-
ment method.
Materials and methods
Sample collection and cell culture
Human impacted third molars were collected from
adults (19–29 years of age) at the dental hospital of
the Fourth Military Medical University. The dental
pulp was isolated as previously described (Gronthos
et al. 2000). All the tooth extractions were conducted
under the approval of the Ethical Committee of the
hospital. Briefly, the pulp tissue was gently separated
from the crown and root and then was digested in a
solution of 3 mg mL1 collagenase type I (Invitrogen,
Carlsbad, CA, USA) and 4 mg mL1 dispase (GIBCO/
Invitrogen, Carlsbad, CA, USA) for 40 min at 37 °C.
Single-cell suspensions of DPSCs were obtained by
passing the solution through a 70-lm strainer and
seeding 1 9 104 cells well1 onto six-well plate
(Corning Costar, Cambridge, MA, USA). The standard
medium was defined as: a-modification of Eagle’s
Medium (a-MEM; GIBCO/Invitrogen) supplemented
with 10% foetal bovine serum (FBS; HyClone, Kerr-
ville, TX, USA); 100 mol L1 L-ascorbic acid 2-phos-
phate (Sigma, St Louis, MO, USA); 2 mmol L1 L-
glutamine (Sigma); 100 U mL1 penicillin; and
100 lg mL1 streptomycin (GIBCO) at 37 °C in 5%
CO2. The medium was changed every 2–3 days. Sin-
gle cells were isolated using the limiting dilution
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technique, and they were seeded onto a 96-well plate
and were allowed to grow into a single colony. A
number of these single-colony-derived strains of
DPSCs were pooled, cultured and passaged at a 1 : 3
ratio when they reached 80% confluence. Next, the
cells were stained with STRO-1, CD146, vimentin
(Sigma), and keratin (Sigma) using immunofluores-
cence staining. Laser scanning confocal microscopy
showed that the cells were STRO-1, CD146 and
vimentin positive and keratin (negative control) nega-
tive. The experiments were performed using the cells
from the third to sixth passages. bFGF (Calbiochem,
San Diego, CA, USA) was prepared according to the
manufacturer’s instructions and was diluted to a
concentration of 10 ng mL1 in standard medium
(a-MEM containing 10% FBS) or standard osteogenic
differentiation medium [standard medium containing
50 mg mL1 ascorbic acid (Sigma), 10 mmol L1
beta-glycerophosphate (BGP; Sigma) and 10 ng mL1
dexamethasone], as previously described (Osathanon
et al. 2011).
In vitro osteogenic differentiation assay
The in vitro osteogenic differentiation assay was
divided into five small assays to detect the effects of
bFGF on the osteogenic differentiation of DPSCs.
In assays 1, 2, 3 and 4, DPSCs were seeded into a
24-well plate at a density of approximately
1 9 105 cells per well and were divided into
experimental and control groups. After reaching 80%
confluence, the cells in the control and experimental
groups were treated with or without bFGF according
to Table 1. In assay 5, DPSCs were seeded into two
25-cm2 cell culture flasks (Corning Incorporated,
Corning, NY, USA) at a density of approximately
1 9 106 and were divided into experimental and con-
trol groups. After reaching 80% confluence, the cells
in the experimental group were pre-cultured in stan-
dard medium with 10 ng mL1 bFGF, and the cells in
the control group were pre-cultured with standard
medium for 1 week. Then, the cells were seeded
into a 24-well plate at a density of approximately
1 9 105 cells per well after subcultivation. The exper-
imental and control groups were cultured with stan-
dard osteogenic differentiation medium for 4 weeks
according to Table 1. After cultivation, all of the cells
were stained with Alizarin red for Alizarin red quanti-
fication experiments, according to the methods devel-
oped by Osathanon et al. (2011). All of the
experiments were performed at least three times.
ALP activity quantification
The DPSCs (200 cells well1) were seeded onto a 96-
well plate and were divided into three groups. Each
group had five wells. In this assay and the following
assays, the cells pre-treated with standard media with
bFGF (10 ng mL1) for 1 week were designated as
group 1, the cells pre-treated with standard media
Table 1 In vitro osteogenic differentiation assay
Assay Group Cell condition Pre-treatment Osteogenic differentiation for 4 weeks
Assay 1 EXP Confluence / Osteogenic differentiation medium
with bFGF
CTR Confluence / Osteogenic differentiation medium
Assay 2 EXP Confluence Standard medium for 1 week Osteogenic differentiation medium
with bFGF
CTR Confluence Standard medium for 1 week Osteogenic differentiation medium
Assay 3 EXP1 Confluence Standard medium with bFGF for 1 week Osteogenic differentiation medium
with bFGF
EXP2 Confluence Standard medium with bFGF for 1 week Osteogenic differentiation medium
CTR Confluence Standard medium for 1 week Osteogenic differentiation medium
Assay 4 EXP1 Confluence Standard medium with bFGF for 2 weeks Osteogenic differentiation medium
with bFGF
EXP2 Confluence Standard medium with bFGF for 2 weeks Osteogenic differentiation medium
CTR Confluence Standard medium for 2 weeks Osteogenic differentiation medium
Assay 5 EXP Confluence Standard medium with bFGF for 1 week
and subcultivation
Osteogenic differentiation medium
CTR Confluence Standard medium for 1 week and
subcultivation
Osteogenic differentiation medium
EXP, experimental; CTR, control; bFGF, basic fibroblastic growth factor.
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with bFGF (10 ng mL1) for 2 weeks were designated
as group 2, and the cells pre-treated with standard
media without bFGF for 1 week were designated as
the control group. After pre-treatment, the culture
media in all of the groups were all changed to stan-
dard osteogenic differentiation medium. The ALP
activity assay was performed on days 2, 4, 6, 8, 10,
12 and 14 after osteogenic differentiation, using an
ALP assay kit (JianCheng Co., Nanjing, China)
according to the manufacturer’s instruction. The
results were measured spectrophotometrically at
520 nm.
Quantification Reverse Transcription Polymerase
Chain Reaction (qRT-PCR)
The DPSCs (1 9 104 cells per dish) were seeded onto
30 mm dishes and were also divided into group 1,
group 2 and the control group. After pre-treatment,
the culture media in all of the groups were all chan-
ged to standard osteogenic differentiation medium.
One week later, total RNA was extracted from the
DPSCs using RNAiso Plus (Takala, Osaka, Japan) and
was reverse transcribed using a Takala reverse trans-
criptase kit (Takala). Real-time PCR was performed
using a standard SYBR Green PCR kit (Takala) and
the Applied Biosystems 7500 Real-Time PCR System
(ABI, Foster City, CA, USA), according to the respec-
tive manufacturers’ instructions. b-actin was used as
an internal control. The expressions of osteogenic dif-
ferentiation marker mRNA, ALP, dentine sialophos-
phoprotein (DSPP), osteocalcin (OCN) and bone
sialoprotein (BSP) were analyzed. Each sample was
analyzed in triplicate. The 2DDCt method was used to
quantify the relative levels of gene expression. The
results represent the ratio between the expression in
the control group and that in the bFGF pre-treatment
groups (log10 scale). The primer sequences are pre-
sented in Table 2.
In vivo osteogenic differentiation assay
Cell culture
The DPSCs (1 9 106 cells per dish) were seeded in 32
10-cm dishes and were divided into group 1, group 2,
a control group and a group called group 3, in which
cells were pre-treated with bFGF (10 ng mL1) for
1 week and were treated with standard medium for
another week (Table 3). After pre-treatment, the cells
in group 1, group 2 and the control group were
treated with standard osteogenic differentiation med-
ium for 1 week.
Cell seeding and transplantation
After cultivation, the DPSCs (1 9 107 cells) in each
dish were seeded into HA/TCP (60/40) pills (diame-
ter = 5 mm, thickness = 1.5 mm) and were trans-
planted subcutaneously into 16 naked mice, which
had been averagely and randomly divided into four
groups. Incision were made in the backs of each
animal and then bilateral blunt dissection created
two pouches. The pills were placed into each side
of the back, which was then sutured. These proce-
dures were performed in accordance with the speci-
fications of an animal protocol approved by the
Ethics Committee of the Fourth Military Medical
University.
Sectioning and staining
The transplants were removed 2 and 3 months after
transplantation, were fixed with 4% paraformalde-
hyde, and then cut into slices and stained using a
Modified Ponceau Trichrome Stain (Oh et al. 2013).
For histometric analysis of cartilage-like and bone-like
tissue formation, computer-assisted histometric mea-
surements were acquired with an automated image
analysis, as previously described (Zhang et al. 2012).
Statistical analysis
The data are expressed as means  SDs. The statisti-
cal significance was evaluated using unpaired or
paired Student’s t-tests for comparisons between two
means, whereas MANOVA was used to evaluate multiple
means. A value of P < 0.05 was assumed to denote
statistical significance.
Table 2 Primer sequences
Primer Sequence (50–30)
Actin-forward TGGCACCCAGCACAATGAA
Actin-reverse CTAAGTCATAGTCCGCCTAGAAGCA
ALP-forward CCACGTCTTCACATTTGGTG
ALP-reverse AGACTGCGCCTGGTAGTTGT
DSPP-forward TCACAAGGGAGAAGGGAATG
DSPP-reverse TGCCATTTGCTGTCAGTTT
OCN-forward GGCAGCGAGGTAGTGAAGAG
OCN-reverse CTGGAGAGGAGCAGAACTGG
BSP-forward AAAGTGAGAACGGGGAACCT
BSP-reverse GATGCAAAGCCAGAATGGAT
DSPP, dentine sialophosphoprotein; OCN, osteocalcin; BSP,
bone sialoprotein; ALP, alkaline phosphatase.
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Results
bFGF affected the osteogenic differentiation of
DPSCs in a treatment-dependent manner
Basic fibroblastic growth factor affected the osteo-
genic differentiation of DPSCs in a treatment-depen-
dent manner. In assay 1, bFGF stimulation during
the osteogenic differentiation period could upregulate
the osteogenic differentiation ability of DPSCs
(Fig. 1a). In assay 2, bFGF stimulation during the
osteogenic differentiation period could upregulate the
osteogenic differentiation ability of DPSCs, regardless
of 1-week pre-treatment with standard medium
(Fig. 1b). In assay 3, after 1 week of pre-treatment
with bFGF, the osteogenic differentiation ability of
DPSCs was increased, regardless of bFGF stimulation
during the osteogenic differentiation period (Fig. 1c).
In assay 4, after 2 weeks of pre-treatment with bFGF,
the osteogenic differentiation ability of DPSCs was
decreased, regardless of bFGF stimulation during the
osteogenic differentiation period (Fig. 1d). In assay 5,
after 1 week of pre-treatment with bFGF, the osteo-
genic differentiation ability of DPSCs was increased
after subcultivation (Fig. 1e). According to the Aliza-
rin red quantification results, the pre-treatment dura-
Table 3 Culture method
Group Cell condition Pre-culture Osteogenic differentiation
Negative control Confluence Standard medium for 1 week Standard osteogenic differentiation
medium for 1 week
Positive control Confluence Standard medium with bFGF for 1 week Standard medium for 1 week
Group1 Confluence Standard medium with bFGF for 1 week Standard osteogenic differentiation
medium for 1 week
Group2 Confluence Standard medium with bFGF for 2 weeks Standard osteogenic differentiation
medium for 1 week
bFGF, basic fibroblastic growth factor.
(a)
(d) (e)
(b) (c)
Figure 1 Alizarin red quantification assay results. Different basic fibroblastic growth factor (bFGF) treatment manners lead to
different results of osteogenic differentiation of dental pulp stem cells (DPSCs) in alizarin red quantification assay 1 (a), 2 (b), 3
(c), 4 (d), 5 (e). The means and the standard errors of the means (SEMs) of three identical experiments are shown. *Indicates
P < 0.05 compared to the control group.
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tion was one of the key factors that determined how
bFGF affected the osteogenic differentiation of the
DPSCs. In assays 1, 2 and 4, bFGF inhibited the oste-
ogenic differentiation of DPSCs. Assays 1 and 2
showed that bFGF stimulation in the osteogenic dif-
ferentiation period decreased the in vitro osteogenic
differentiation ability of DPSCs. In addition, no signifi-
cant differences were found between cells that had
just reached confluence and cells cultured for 1 week.
There was no significant difference between cells that
were not pre-treated with bFGF, and cells that were
pre-treated with bFGF for 2 weeks in assay 4. How-
ever, in assays 3 and 5, in which the DPSCs were
pre-treated with bFGF for 1 week, the osteogenic dif-
ferentiation of the DPSCs was enhanced. Assay 5 also
showed that the impact of bFGF on DPSCs could be
transferred to the next passage because assay 5
showed similar results to assay 3 after subculture.
Based on these results, ALP activity quantification
and qRT-PCR were performed, which showed supple-
mental results. In both assays, group 1 refers to
1 week of bFGF pre-treatment, group 2 refers to
2 weeks of bFGF pre-treatment, and control group
refers to 1 week of standard medium pre-treatment.
ALP activity quantification was performed every
2 days from the initiation of osteogenic differentia-
tion. Interestingly, the absorbance value (wave-
length = 520 nm) of group 1 was higher than that in
the control group beginning on day 6, whereas the
absorbance value of group 2 was lower than that in
the control group beginning on day 6 (Fig. 2a).
qRT-PCR results showed that the expressions of ALP,
DSPP, OCN and BSP of the DPSCs in group 1, in
which DPSCs were pre-treated with bFGF for 1 week,
were higher than in the control group, and the
expressions of ALP, DSPP, OCN and BSP of the DPSCs
in group 2, in which DPSCs were pre-treated with
bFGF for 2 week, were lower than in the control
group (Fig. 2b).
bFGF affected the in vivo osteogenic differentiation
of DPSCs depending on the duration of
pre-treatment
Two months after transplantation
After 2 months, cartilage-like tissues (stained in
blue) were formed in the edge of the hole in the
control group (Fig. 3a), and there were cartilage-like
tissues formed in the middle of the hole in group 1
(Fig. 3b). Obvious cartilage- or bone-like tissue for-
mation was not observed in group 2 (Fig. 3c) or
group 3 (Fig. 3d). However, well-developed vascular
tissue was only observed in group 3. Histometric
measurements showed that there were more carti-
lage-like tissues formed in group 1 than in the con-
trol group (Fig. 5a). In addition, little bone
formation was observed in any of the groups
(Fig. 5b).
Three months after transplantation
After 3 months, cartilage (stained in blue) – and
bone-like (stained in red) tissue formation was
observed in the control group (Fig. 4a) and in group
1(Fig. 4b). Obvious cartilage- or bone-like tissues
(a) (b)
Figure 2 Alkaline phosphatase (ALP) activity quantification and qRT-PCR results. ALP activity quantification (a) and qRT-PCR
(b) results showed that 1 week/2 weeks of pre-treatment with basic fibroblastic growth factor (bFGF) increased/decreased the
osteogenic differentiation ability of dental pulp stem cells (DPSCs). The means and the standard errors of the means (SEMs) of
three identical experiments are shown. *Indicates P < 0.05 compared to the control group.
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formation was also not observed in group 2 (Fig. 4c)
or group 3 (Fig. 4d). There was well-developed vascu-
lar tissue formation in group 3, which was not
observed in the other groups. Histometric measure-
ments showed that there were more bone-like tissues
formed in group 1 than in the control group
(Fig. 5d), but there were no significant differences in
the cartilage-like tissue formation between group 1
and the control group (Fig. 5c).
The in vivo results were similar to the in vitro
results. Thus, this experiment confirmed the results of
the in vitro experiments.
(a) (b)
(c) (d)
Figure 3 Two-month in vivo osteogenic differentiation assay. Different basic fibroblastic growth factor (bFGF) treatment man-
ners lead to different results of osteogenic differentiation of dental pulp stem cells (DPSCs) in the in vivo osteogenic differentia-
tion assay after 2 months transplantation.
(a) (b)
(c) (d)
Figure 4 Three-month in vivo osteogenic differentiation assay. Different basic fibroblastic growth factor (bFGF) treatment man-
ners lead to different results of osteogenic differentiation of dental pulp stem cells (DPSCs) in the in vivo osteogenic differentia-
tion assay after 3 months transplantation.
bFGF affects DPSC mineralizing Qian et al.
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Discussion
Several interesting and confusing results appear in
the literature, which indicate that the nature of bFGF
action is complex and that the biological effects of
bFGF could depend on the differentiation stage of os-
teoblasts and the length and mode of exposure to cer-
tain factors (Fakhry et al. 2005). In the present study,
an experiment was performed on how different bFGF
stimulation conditions affected the osteogenic differen-
tiation of DPSCs, and so, 1 and 2 weeks of stimula-
tion of bFGF was chosen as the treatment protocol
because these durations have been frequently used in
previous studies (Shiba et al. 1995, He et al. 2008,
Shimabukuro et al. 2009, Osathanon et al. 2011).
The Alizarin red quantification assay was divided into
five small assays. The main assay division indicated
the differences between the stimulation time and
order. The bFGF stimulation of DPSCs was divided
into the pre-treatment period and the osteogenic
differentiation period. As observed from the results,
the difference in the stimulation time and order led to
different osteogenic differentiation abilities of DPSCs.
bFGF treatment did not stimulate proliferation of
human calvarial bone cells that had been grown in
mineralizing medium for several weeks (Debiais et al.
1998). As shown in assays 1 and 2, bFGF stimulation
during the osteogenic differentiation period decreased
the osteogenic differentiation of DPSCs, regardless of
the cell condition (confluence or multilayer). Fakhry
et al. (2005) found that the mitogenic effects of bFGF
were more evident in maturing osteoblasts than in
osteogenic pre-cursor cells. Assay 4 showed that
2 weeks of pre-treatment with bFGF decreased the
osteogenic differentiation ability of DPSCs regardless
of bFGF stimulation during the osteogenic differentia-
tion period. However, the lack of mitogenic effect
might have resulted from the onset of mineralization
(Fakhry et al. 2005). With 1 week of pre-treatment
with bFGF, the osteogenic differentiation ability of the
(a) (b)
(c) (d)
Figure 5 Quantitative analysis of the in vivo osteogenic differentiation assay. The results of the in vivo osteogenic differentiation
assays were statistically confirmed by histometric measurements. *Indicates P < 0.05.
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DPSCs was increased regardless of bFGF stimulation
during osteogenic differentiation period. Assays 3 and
4 indicated that the pre-treatment period was vital for
the osteogenic differentiation of DPSCs in vitro. Assay
5 showed that the impact of bFGF could be inherited.
In other words, these phenomena indicated that the
impact of bFGF on DPSCs occurred at the genetic level
and was not abolished by subcultivation. According to
these results, it can be concluded that 1 week of pre-
treatment with bFGF increased the in vitro osteogenic
differentiation ability of DPSCs. However, these effects
were not time dependent: 2 weeks of pre-treatment
with bFGF decreased the in vitro osteogenic differenti-
ation ability of DPSCs. This finding could have been
due to bFGF playing different roles depending on the
differentiation stage of DPSCs into osteoblasts (Fakhry
et al. 2005). In addition, the ALP activity quantifica-
tion assay and qRT-PCR results also confirmed that
the pre-treatment period was vital for the osteogenic
differentiation of DPSCs in vitro.
In the in vivo experiments, the same results were
obtained. One week of pre-treatment with bFGF
increased the formation of cartilage- and bone-like
tissues, whereas 2 weeks of pre-treatment with bFGF
decreased cartilage- and bone-like tissue formation.
In the experiments, cell-scaffold complexes were col-
lected after 2 and 3 months. After 2 months, the
cartilage- and bone-like tissue formation of the
DPSCs was not obvious, even in the control group
and in group 1. After 3 months, cartilage- and
bone-like tissues were remarkably formed in the con-
trol group and in group 1. However, group 2 and
group 3 still exhibited no significant cartilage- or
bone-like tissue formation. Therefore, it was con-
cluded that obvious cartilage- and bone-like tissue
formation could be observed after 3 months; thus,
the in vivo experiment should last 3 months. It was
also concluded that 1 week of pre-treatment with
bFGF could increase the in vivo osteogenic differenti-
ation ability of DPSCs, whereas 2 weeks of pre-
treatment with bFGF would decrease the in vivo
osteogenic differentiation ability of DPSCs.
The wound healing process is activated when den-
tine injury occurs. The wound healing process could
offer another explanation for the results. Previous
research has shown that bFGF played an important
role in the wound healing process (Smith 2002,
Tran-Hung et al. 2008). The pre-treatment period in
the present study could be considered the preliminary
stage of wound healing. During this stage, there was
little osteogenic differentiation induction component
in the cellular matrix. The main function of bFGF was
the promotion of the proliferation and migration of
DPSCs (Shimabukuro et al. 2009). According to the
results, 1 week of pre-treatment with bFGF could pro-
mote the osteogenic differentiation of DPSCs, and this
result indicated that DPSCs could differentiate into
osteoblast-like cells more easily with stimulation by
bFGF and participate in the preliminary stages of
wound healing. Previous research showed that
2 weeks of stimulation with bFGF could attenuate the
osteogenic differentiation-related mRNA expression of
collagen type I, osteonectin, BSP and DSPP (Shima-
bukuro et al. 2009). These results were similar to
those of the present study. Furthermore, Osathanon
et al. (2011) reported that 2 weeks of bFGF stimula-
tion would enhance the stemness of DPSCs by upre-
gulating OCT4, NANOG1 and REX1, which was an
additional finding that indicated that 2 weeks of bFGF
stimulation could attenuate the osteogenic differentia-
tion of DPSCs. Thus, it can be deduced that bFGF can
activate DPSCs by upregulating the proliferation,
migration and osteogenic differentiation of DPSCs dur-
ing the preliminary stage of wound healing. In con-
trast, bFGF attenuates the osteogenic differentiation
and maintains the stemness of the DPSCs, which is
not activated in the preliminary stages of wound
healing. This mechanism will maintain the population
of DPSCs in the dental pulp during the wound healing
process.
The osteogenic differentiation of dental pulp tissue
is a double-edged sword. When dental pulp is sub-
jected to harmful stimulation, the osteogenic differen-
tiation of the odontoblasts or the odontoblast-like cells
can form reactive or reparative dentine, which pro-
tects the dental pulp from further damage. It is
known that DPSCs can differentiate into odontoblasts
or odontoblast-like cells. However, during age-related
changes and chronic inflammation of the dental pulp,
the osteogenic differentiation of dental pulp cells will
produce pulp stones and will form calcifications in the
dental pulp cavity and root canal, which will make
root canal treatment more complicated. It is known
that DPSCs are mostly located in multicellular layers,
and that these cells are relevant to the calcification
obtained after calcium hydroxide pulp capping and
pulpotomy. Therefore, the present study found a new
method to control the osteogenic differentiation of
dental pulp tissue with bFGF, to obtain the desired
osteogenic differentiation state, which could bring
great changes to the field of endodontic tissue engi-
neering and endodontic therapy.
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Conclusion
One week of pre-treatment with bFGF increased the
in vitro and in vivo osteogenic differentiation ability of
DPSCs, whereas 2 weeks of pre-treatment with bFGF
decreased the in vitro and in vivo osteogenic differenti-
ation ability of DPSCs. Furthermore, the pre-treat-
ment duration was vital for the osteogenic
differentiation of DPSCs in vitro and in vivo. bFGF
affected the osteogenic differentiation of DPSCs in a
treatment-dependent manner both in vitro and in vivo.
The data suggest that different treatment periods and
durations could have opposite effects when the same
cells were treated with the same cytokines. For future
studies of DPSCs and bFGF, the stature of the DPSCs
and treatment protocol with bFGF must be the pri-
mary considerations for all of the variables because a
slight change in the stature of the DPSCs or the treat-
ment protocol with bFGF could result in great
changes to the result when DPSCs were treated by
bFGF.
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